VIDEO: Immunotherapy ups disease control rate in relapsed mesotheliomaJune 6, 2017Lung CancerImmuno-oncology
VIDEO: Combined immunotherapy strategy shows promise in advanced solid tumorsJune 6, 2017Immuno-oncologyImmunotherapy
Immune-agonist combo has activity against several tumor typesJune 5, 2017Immuno-oncologyImmunotherapyBreast CancerMelanomaRenal Cell CarcinomaGynecologic CancerGenitourinary Cancer
FDA approves pembrolizumab for advanced urothelial carcinomaMay 18, 2017Genitourinary CancerImmuno-oncology
Pembrolizumab shows some activity against advanced endometrial cancerMay 18, 2017Gynecologic CancerImmuno-oncology
Salvage chemo for NSCLC more effective after PD-1/PD-L1 inhibitorsMay 15, 2017Lung CancerImmuno-oncology
Atezolizumab improves OS in NSCLC with brain metastasesMay 12, 2017Lung CancerNeuro-oncologyImmuno-oncology
FDA approves pembrolizumab for first-line advanced NSCLCMay 12, 2017Lung CancerImmunotherapyImmuno-oncology
SLE linked to subsequent risk of malignant melanomaMay 11, 2017MelanomaPreventive CareImmuno-oncology
Flu shots may spark immune adverse events in PD-1 blockade for NSCLCMay 7, 2017ImmunotherapyLung CancerImmuno-oncology
Pembrolizumab advances in relapsed/refractory classic Hodgkin lymphomaMay 2, 2017Lymphoma & Plasma Cell DisordersImmuno-oncology
Get ready for cancer immunotherapy-induced rheumatic diseasesApril 3, 2017ImmunotherapyMelanomaImmuno-oncology
VIDEO: It’s too early to give up on immunotherapy for breast cancerMarch 12, 2017Breast CancerImmuno-oncology
